Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 21,950 call options on the stock. Thisisanincreaseofapproximately54% compared to the typical daily volume of 14,292 call options.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on SRPT shares. Scotiabank raised Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price objective on the stock in a research note on Friday, June 6th. Leerink Partners reissued a "market perform" rating on shares of Sarepta Therapeutics in a research note on Monday, July 21st. JPMorgan Chase & Co. raised Sarepta Therapeutics from an "underweight" rating to a "neutral" rating and set a $24.00 target price on the stock in a research note on Tuesday. Jefferies Financial Group cut their price target on Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating for the company in a report on Thursday, July 24th. Finally, Needham & Company LLC reaffirmed an "underperform" rating on shares of Sarepta Therapeutics in a report on Monday. Six research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $49.12.
Get Our Latest Analysis on SRPT
Sarepta Therapeutics Trading Down 3.0%
Shares of Sarepta Therapeutics stock traded down $0.49 during trading hours on Friday, reaching $15.93. 3,742,666 shares of the company's stock were exchanged, compared to its average volume of 5,734,218. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -5.93 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The company has a fifty day moving average of $24.24 and a 200-day moving average of $61.50. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $145.00.
Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The firm's revenue for the quarter was up 80.2% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.
Hedge Funds Weigh In On Sarepta Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital International Investors lifted its position in shares of Sarepta Therapeutics by 38.9% during the fourth quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $126,315,000. Aberdeen Group plc increased its stake in shares of Sarepta Therapeutics by 91.1% in the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company's stock valued at $21,500,000 after purchasing an additional 592,125 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock valued at $45,477,000 after purchasing an additional 580,123 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock valued at $168,907,000 after purchasing an additional 577,848 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.